ProCE Banner Activity

Phase I/II Evaluation of Novel BTKi PRN1008 in R/R Primary or Secondary Immune Thrombocytopenia

Slideset Download
Conference Coverage
Early-stage data suggest rapid, durable activity of the novel Bruton tyrosine kinase inhibitor PRN1008 in heavily pretreated patients with relapsed/refractory ITP.

Released: December 10, 2019

Expiration: December 08, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company